Table 3.

MIS-C National Clinical Trials (NCT) Listed in PubMed.

# NCT No. Abbreviated Study Description Age Patients, n Status
1 04456439 Intermediate-size EAP (MSC) for MIS-C associated with COVID-19 2mo–17y ~50 Available
2 04588363 OS in COVID-19 infections and MIS-C <20y 250 Recruiting
3 04538495 OS: characterization of MIS-C and its relationship to Kawasaki Disease >1mo 100 Recruiting
4 04640038 Contrast-enhanced ultrasound in COVID-19 <17y 30 Recruiting
5 04659486 Adolescents with COVID-19/MIS-C at HCFMUSP 7–18y 100 Enrolling by invitation
6 04549285 MSC infusions in children with MIS-C 18–20y 6 Not yet recruiting

EAP, expanded access program; HCFMUSP, Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paolo, Brazil; mo, month; MIS-C, multisystem inflammatory syndrome in children; MSC, mesenchymal stromal cells; OS, observational study; y, year.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2021 April; 12(2): e0010. ISSN: 2076-9172
Published online 2021 April 29. doi: 10.5041/RMMJ.10433.